The underlying disease of infection was 20%, EBV associated secondary HLH (20%), lymphoma associated secondary HLH (10%), primary HLH with perforin and STX II mutations (10%), HLH unknown origins (40%). Among 20 patients of the study sample, 50% of patients discharged at the first course of treatment.